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Advances in secondary prevention of coronary
heart disease have contributed significantly to the
decline in cardiovascular mortality in the past
decades [1]. Antithrombotic agents, betablockers,
ACE inhibitors as well as lipid lowering drugs are
associated with a clinically significant reduction in
subsequent acute coronary syndromes, need for
revascularisation and mortality [2–9]. Several stud-
ies have found an under use of cardiovascular drugs
among outpatients with CHD [10–13]. A recent
survey conducted among outpatients with a history
of acute coronary syndromes or coronary revascu-
larisation <70 years of age in Europe (EURO-
ASPIRE [14,15]) has shown that drug therapy 
has improved over time, but that blood pressure
and lipid goals still have not been reached in a large
proportion of the study population. Comparable
data for Switzerland is lacking. We, therefore, as-
sessed drug therapy in a representative sample of
outpatients in Switzerland.
Background: Secondary prevention of coronary
artery disease markedly reduces cardiovascular
mortality and non-fatal endpoints. Outpatient care
of subjects with coronary artery disease has been
assessed in several European countries, but no
current data is available for Switzerland.
Methods: A random sample of office-based
physicians across Switzerland recorded current
drug prescription of outpatients with coronary
artery disease in the years 2000/2001 by means of
a mail questionnaire. We assessed treatment fre-
quencies according to different patient character-
istics.
Results: 565 patients were included (mean age
68 ± 11 years, 75% male). There was no evidence
for differences in drug utilisation among the re-
gions. Drug prescription rates for antithrombotic
agents, beta-blockers, ACE-inhibitors/angio-
tensin receptor blockers and lipid lowering drugs
were 91%, 58%, 50% and 63% respectively.
Lower treatment rates were observed among pa-
tients >70 years and in those without a history of
myocardial infarction or coronary revascularisa-
tion. Forty-nine percent of the patients had a blood
pressure >140/>90, and 60% had lipid readings
above the intervention cut-off according to the
Swiss recommendations. Among those without a
history of myocardial infarction or coronary revas-
cularisation, the respective figures were 60% and
80%. 
Conclusions: Compared to former surveys evi-
dence based drug prescription has improved in
Switzerland. Despite  this, therapeutic goals for
cholesterol levels and blood pressure are not being
reached in a large proportion of patients. A high
risk group for under use of evidence based drugs
are patients without a history of myocardial in-
farction or coronary revascularisation.
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Results
565 patients were included. Patient character-
istics are given in table 1. Mean age was 68 ± 11
years and 75% were male. 53% of the patients had
a history of myocardial infarction and 62% had had
a coronary revascularisation.
The prescription rates of antithrombotic
agents, beta-blockers, ACE-inhibitors/angioten-
sin receptor blockers and lipid lowering drugs 
were 91%, 58%, 50% and 63% respectively. Drug
prescription according to different characteristics
is shown in table 2. There were no significant dif-
ferences in drug utilisation between the French,
Italian and German speaking regions of Switzer-
land. In patients >70 years of age beta-blockers and
particularly lipid lowering drugs were less often
prescribed compared to those <70 years of age.
Among women, utilisation of antithrombotic
agents was lower in the unadjusted and age-ad-
justed analysis compared to men but when results
were stratified according to history of myocardial
infarction or revascularisation, there was no mate-
rial difference in treatment between men and
women (results not shown). For the other cardio-
vascular drugs, the age-adjusted prescription rates
were virtually identical between the sexes (58% vs.
58%, 50% vs. 50% and 63% vs. 62% for beta-
blockers, ACE-inhibitors/angiotensin receptor
blockers and lipid lowering drugs respectively).
Among patients with a recent myocardial infarc-
tion, beta-blocker use was 87%, whereas of those
with a remote or no history of myocardial infarc-
tion about 50% received a beta-blocker. In patients
with myocardial infarction, prescription of anti-
thrombotic agents and lipid lowering drugs was
also higher as was true for patients who had had a
prior coronary revascularisation. For antithrom-
botic agents and lipid lowering drugs, the largest
differences in drug prescription were observed be-
tween patients who had either a history of myo-
cardial infarction or coronary revascularisation
compared to those who had neither. Patients who
had a history of these conditions received anti-
thrombotic agents and lipid lowering drugs in 96%
and 71% respectively, whereas those without re-
ceived the respective drugs in only 73% and 36%
(table 2). 
Characteristics number/mean percent/± SD
Total sample 565 100%
Age (years) 68 ±11
Male sex 422 75%
Cardiovascular risk factors
Hypertension 368 65%
Diabetes mellitus 124 22%
Hyperlipidaemia 403 71%
Current smoking 97 17%
History of coronary artery disease (CAD)
Myocardial infarction 297 53%
Coronary revascularisation 349 62%
Hospital stay for CAD within 
the past 12 months 180 32%
Table 1
Patient characteris-
tics of the study
population.
Methods
In Autumn 2000, we sent a letter to 650 Swiss office-
based general practitioners, internists and cardiologists,
who had been randomly selected from a list of all office-
based Swiss physicians. In this survey they were asked to
record the next two patients with coronary heart disease
(CHD) presenting in their office. Participants filled in a
questionnaire on these patients including important pa-
tient characteristics and medications. Physicians who did
not respond within six weeks were reminded with a sec-
ond letter. Of the physicians who still did not respond, we
drew a random sample of 100 and motivated them to par-
ticipate. With this procedure, crude participation rate was
45% (n = 290) and 50% after correction for non-eligible
physicians. There were no differences between patients of
physicians who answered to the first and second letter and
those who did not respond until the phone call. We also
externally validated this enrolment procedure with a
traditional chart review in 30 medical offices with 202 pa-
tients. There was no difference among the samples with
respect to age, sex, risk factors and drug prescription rates
(all p >0.2).
Statistical analysis
We calculated proportions and mean values ± SD of
the patient characteristics. For the different cardiovascu-
lar drugs, crude and age-standardised proportions were
calculated overall and according to different patient char-
acteristics. The groups were compared with the Pearson
chi2 test and logistic regression respectively. Analyses were
performed with SAS 8.1. All p-values are two-sided. 
P-values <0.05 were viewed as significant.
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In table 3, blood pressure and lipid readings
are shown. Forty nine percent of the patients had
a blood pressure >140/>90, 64% had cholesterol
levels >5 mmol/L and 60% were above the inter-
vention cut-off according to the Swiss guidelines
for lipid lowering drugs [16]. In patients >70 years,
blood pressure control was comparable to the
overall study population (blood pressure >140/
>90: 50%), but a higher proportion of older pa-
tients had lipid levels above the intervention cut-
off according to the Swiss guidelines (66%). As ex-
pected from drug prescription, blood pressure and
lipid control was particularly unfavourable among
patients without prior myocardial infarction or
revascularisation. Sixty-four percent had blood
pressure levels above the cut-off of 140/90, 83%
had a cholesterol level >5 mmol/L and 80% were
above the Swiss intervention cut-off for lipid low-
ering drugs.
In table 4, we present drug prescription in the
Swiss subset comparable with the selection crite-
ria of the EUROASPIRE II study population (age
<70 years, history of myocardial infarction or
revascularisation). In the Swiss sample the propor-
tion that received antithrombotic agents, beta-
blockers and lipid lowering drugs tended to be
higher compared to the EUROASPIRE II study
population. Blood pressure control was slightly
better in the Swiss study population. Despite the
superior prescription rate of lipid lowering drugs,
however, the proportion of patients with a choles-
terol level >5 mmol/L was similar.
Characteristics antithrombotic agents (%) beta-blockers (%) ACE-I/ARBs (%) lipid-lowering drugs (%)
crude age-adjust. crude age-adjust. crude age-adjust. crude age-adjust.
German-speaking part of CH 93 93 60 60 51 51 61 61
French-speaking part of CH 89 89 51 50 54 57 68 69
Italian-speaking part of CH 88 88 62 63 38 41 67 66
Age ≤70 years 92 – 65* – 48 – 77* –
Age >70 years 90 – 51 – 52 – 46 –
Male 93* 93** 59 58 50 50 67* 63
Female 86 85 55 58 50 50 50 62
Myocardial infarction <12 months 94** 95*** 86* 87* 52 55 77** 75**
Myocardial infarction >12 months 95 95 59 56 52 55 69 69
Myocardial infarction, time unknown 97 87 60 53 55 51 61 52
No prior myocardial infarction 87 87 51 52 44 45 55 56
Coronary revascularisation 97* 97*** 62‡ 60 51 50 79* 75*
No coronary revascularisation 80 80 52 54 49 48 37 44
Myocardial infarction or coronary 
revascularisation 96* 96* 61† 60 48 48 73* 71*
Neither myocardial infarction 
nor coronary revascularisation 74 73 48 51 50 50 30 36
Total 91 91 58 58 50 50 63 63
*: p <0.001, **: p <0.01, ***: p <0.05
Table 2
Unadjusted and age-adjusted prescription rates of cardiovascular drugs among outpatients with coronary artery disease according to different 
characteristics, Switzerland 2000/2001.
Blood pressure/lipid parameters Number/ Percent/
Mean ±SD
Systolic blood pressure 136 ±16
Diastolic blood pressure 80 ±9
Blood pressure >140/>90 mm Hg 274 49%
Total cholesterol (mmol/L) 5.3 ±1.1
Total cholesterol >5 mmol/L 363 64%
LDL cholesterol >3 mmol/L 342 62%
Lipid readings above Swiss lipid 
lowering drug intervention cut-off 337 60%
Table 3
Blood pressure and
lipid levels among
Swiss outpatients
with coronary heart
disease.
Medications Switzerland, EUROASPIRE II
2000/2001 1999/2000
Antiplatelet agents 84%* 86%
Anti-coagulants 15% 7%
Beta-blockers 71% 63%
ACE-inhibitors 35%** 38%
Lipid lowering drugs 82% 61%
Blood pressure/lipid levels
Blood pressure 
>140/>90 mm Hg 43% 51%***
Cholesterol >5 mmol/L 56% 58%
* antiplatelet agents or oral anticoagulants 95%
** ACE-inhibitors or renin-angiotensin receptor blockers 47%.
*** Classification derived from the mean values of 2 measure-
ments.
Table 4
Drug prescription in
Switzerland among
patients <70 years of
age with a history of
myocardial infarction
or coronary revascu-
larisation (n = 260) 
as compared to the
therapy in other 
European countries
(EUROASPIRE II).
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This survey assessing drug therapy among
outpatients with coronary artery disease in
Switzerland shows that evidence-based drug
prescription has improved compared to former
surveys. Despite this, guideline goals for blood
pressure and lipid levels were only reached in a
minority of patients. Moreover, those without a
history of myocardial infarction or coronary revas-
cularisation had a clearly inferior drug therapy.
Antithrombotic agents, beta-blockers, ACE-
inhibitors/ARBs and lipid lowering drugs were
prescribed to 91%, 58%, 50% and 63% of the
study population respectively. There is only lim-
ited data from previous Swiss studies with which
to compare the current results [17, 18]. In a small
series of outpatients five years after PTCA in 1994,
83%, 61%, 11% and 33% had been prescribed an-
tithrombotic agents, beta-blockers, ACE-in-
hibitors and lipid lowering drugs respectively [17],
indicating that, with the exception of beta-block-
ers, prescription of these drugs has increased. In
comparison to the EUROASPIRE II study [14, 15]
representing current drug therapy in other Euro-
pean countries, drug prescription in Switzerland
was slightly higher. Nevertheless, 49% of the study
population had blood pressure readings above
140/90, and 60% had lipid values above the inter-
vention cut-off of the Swiss recommendations for
intervention of lipid lowering drugs.
Analysis of specific patient groups demon-
strated a homogeneous prescription pattern of car-
diovascular drugs across Switzerland. In line with
a Swiss survey among outpatients with heart fail-
ure [19] there was no evidence of an under-pre-
scription in women compared to men. Patients
older than 70 years had lower prescription rates of
beta-blockers and lipid lowering drugs, but the use
of antithrombotic agents and ACE-inhibitors/
ARBs was similar in younger and older patients.
Blood pressure control was similar in older and
younger subjects, whereas a higher proportion of
older patients had increased lipid levels compared
to those who were younger. These findings do not
suggest that there is a de facto rationing of medical
care in the elderly due to advanced age in general
as previously suggested [20]. For beta-blockers as-
sumed or real side effects in older patients may
have accounted for the reduced prescription rate.
Since lipid lowering drugs have an excellent toler-
ability, this potential explanation does not apply to
these drugs. A possible cause is that in contrast to
antihypertensive drugs, the broad indication for
lipid lowering drugs is relatively new. The first
large scale clinical trial of statins dating back to
1994 included patients up to 70 years of age [6]. In
subsequent studies the benefit was confirmed
among patients up to 75 years [7, 8] and 80 years
[9], respectively. Therefore there is no rationale to
withholding lipid lowering drugs from older pa-
tients.
As in previous studies [18] patients with his-
tory of myocardial infarction and coronary revas-
cularisation had higher treatment rates of evi-
dence-based cardiovascular drugs compared to
those without. Indeed, patients without a history
of these conditions had surprisingly low treatment
rates for antithrombotic agents and lipid lowering
drugs. Two thirds had a blood pressure >140/>90
and 80% had lipid readings above the intervention
cut-off for lipid lowering drugs. The cause for this
large gap is not quite clear. A defined coronary
event or a coronary intervention may be a time
point for reconsideration of the established drug
therapy and the patients may be better motivated
to use additional medications. Moreover, patients
with a cardiovascular event are hospitalised and
treatment with relatively new drugs such as lipid
lowering drugs is likely to be more rapidly imple-
mented than in outpatient care. It is important that
primary care physicians are made aware of the ten-
dency to under treat patients without myocardial
infarction and coronary revascularisation. Sec-
ondary prevention should be implemented early 
to prevent a first acute coronary syndrome and 
to reduce not only the risk of sudden death but 
also of non-fatal consequences such as subse-
quent chronic heart failure after a myocardial
infarction.
Our study has potential limitations. We had a
response rate of 50% of the eligible physicians.
This is an average response rate to surveys ad-
dressing physicians [21] but we cannot exclude the
possibility that the true prescription rate of drugs
may deviate to some extent from the current re-
sults. It is often assumed that respondents have a
better quality of care than non-respondents. If so,
this would suggest that there is an even higher
number of patients in whom the therapeutic goals
are not being reached. The mail-questionnaire de-
sign with enrolment of two consecutive patients
could result in a bias if physicians had selected cases
with above average quality of care. However, a
validation study, assessing drug prescription by
means of chart review by an external reviewer, 
rendered similar results. Non-standardisation 
of measurements may increase the variability of
the results, but is unlikely to importantly affect
them. 
In summary, our study demonstrates that com-
pared to former surveys prescription rates for car-
diovascular medications among outpatients with
coronary artery disease in Switzerland have im-
proved, but it also shows that control of blood
pressure and lipid levels is still limited. In patients
without prior myocardial infarction or revascular-
isation drug prescription was inferior. Better
awareness regarding the need for early treatment
of patients without a history of hard cardiovascu-
lar endpoints and refined drug therapy among the
remaining patients could not only further reduce
Discussion
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cardiovascular mortality but also non-fatal cardio-
vascular endpoints with subsequently reduced
quality of life. 
We are indebted to the participating physicians for
their detailed records. 
Correspondence:
PD Dr. Jörg Muntwyler
Department of Internal Medicine
C-Hör 47
Rämistrasse 100
CH-8091 Zurich
E-mail: joerg.muntwyler@dim.usz.ch
References
1 Hunink MG, Goldman L, Tosteson AN, Mittleman MA, Gold-
man PA, Williams LW, et al. The recent decline in mortality
from coronary heart disease, 1980–1990. The effect of secular
trends in risk factors and treatment. JAMA 1997;277:535–42.
2 Collaborative overview of randomised trials of antiplatelet ther-
apy-I: Prevention of death, myocardial infarction, and stroke by
prolonged antiplatelet therapy in various categories of patients.
Antiplatelet Trialists’ Collaboration. BMJ 1994;308:81–106.
3 Timolol-induced reduction in mortality and reinfarction in
patients surviving acute myocardial infarction. N Engl J Med
1981;304:801–7.
4 A randomized trial of propranolol in patients with acute
myocardial infarction. I. Mortality results. JAMA 1982;247:
1707–14.
5 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Ef-
fects of an angiotensin-converting-enzyme inhibitor, ramipril,
on cardiovascular events in high-risk patients. The Heart
Outcomes Prevention Evaluation Study Investigators. N Engl
J Med 2000;342:145–53.
6 Randomised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Survival
Study (4S). Lancet 1994;344:1383–9.
7 Prevention of cardiovascular events and death with pravastatin
in patients with coronary heart disease and a broad range of
initial cholesterol levels. The Long-Term Intervention with
Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl
J Med 1998;339:1349–57.
8 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD,
Cole TG, et al. The effect of pravastatin on coronary events
after myocardial infarction in patients with average cholesterol
levels. Cholesterol and Recurrent Events Trial investigators. 
N Engl J Med 1996;335:1001–9.
9 MRC/BHF Heart Protection Study of cholesterol lowering
with simvastatin in 20,536 high-risk individuals: a randomised
placebo-controlled trial. Lancet 2002;360:7–22.
10 Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM.
Do ‘America’s Best Hospitals’ perform better for acute myo-
cardial infarction? N Engl J Med 1999;340:286–92.
11 Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade
on mortality among high-risk and low-risk patients after myo-
cardial infarction. N Engl J Med 1998;339:489–97.
12 Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A,
Marciniak TA. National use and effectiveness of beta-blockers
for the treatment of elderly patients after acute myocardial
infarction: National Cooperative Cardiovascular Project.
JAMA 1998;280:623–9.
13 Krumholz HM, Radford MJ, Wang Y, Chen J, Marciniak TA.
Early beta-blocker therapy for acute myocardial infarction in
elderly patients. Ann Intern Med 1999;131:648–54.
14 Clinical reality of coronary prevention guidelines: a comparison
of EUROASPIRE I and II in nine countries. EUROASPIRE I
and II Group. European Action on Secondary Prevention by In-
tervention to Reduce Events. Lancet 2001;357:995–1001.
15 Lifestyle and risk factor management and use of drug therapies
in coronary patients from 15 countries; principal results from
EUROASPIRE II Euro Heart Survey Programme. Eur Heart
J 2001;22:554–72.
16 Battegay E, Bertel O, Darioli R, Gutzwillwer F, Keller U, Mor-
dasini R, et al. Empfehlungen 1999 zur Behandlungsindikation
des Risikofaktors Cholesterin. Schweizerische Ärztezeitung
1999;80:549–52.
17 Muntwyler J, Maschio, Andrist M, Amann FW. Secondary
prevention in patients before and after percutaneous translumi-
nal coronary angioplasty: 5-year follow-up. Schweiz Med
Wochenschr 1997;127:573–8.
18 Hunziker P, Bertel O. Secondary prevention in chronic coro-
nary heart disease. Schweiz Med Wochenschr 1997;127:254–
60.
19 Muntwyler J, Follath F. Medical treatment of heart failure: an
analysis of actual treatment practices in outpatients in Switzer-
land. The Swiss ‘IMPROVEMENT of HF’ Study Group.
Schweiz Med Wochenschr 2000;130:1192–8.
20 Jenni D, Osterwalder R, Osswald S, Buser P, Pfisterer M. Evi-
dence for age-based rationing in a Swiss university hospital.
Swiss Med Wkly 2001;131:630–4.
21 Asch DA, Jedrziewski MK, Christakis NA. Response rate to
mail surveys published in medical journals. J Clin Epidemiol
1997;50:1129–36.
What Swiss Medical Weekly has to offer:
• SMW’s impact factor has been steadily 
rising, to the current 1.537
• Open access to the publication via
the Internet, therefore wide audience 
and impact
• Rapid listing in Medline
• LinkOut-button from PubMed 
with link to the full text 
website http://www.smw.ch (direct link
from each SMW record in PubMed)
• No-nonsense submission – you submit 
a single copy of your manuscript by 
e-mail attachment 
• Peer review based on a broad spectrum 
of international academic referees
• Assistance of our professional statistician
for every article with statistical analyses
• Fast peer review, by e-mail exchange with
the referees 
• Prompt decisions based on weekly confer-
ences of the Editorial Board
• Prompt notification on the status of your
manuscript by e-mail
• Professional English copy editing
• No page charges and attractive colour 
offprints at no extra cost
Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich 
(Editor in chief)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne
International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, 
The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy
We evaluate manuscripts of broad clinical
interest from all specialities, including experi-
mental medicine and clinical investigation.
We look forward to receiving your paper!
Guidelines for authors:
http://www.smw.ch/set_authors.html
All manuscripts should be sent in electronic form, to:
EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnsburgerstrasse 8
CH-4132 Muttenz
Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch
Swiss Medical Weekly: Call for papers
Swiss 
Medical Weekly
The many reasons why you should 
choose SMW to publish your research 
Official journal of
the Swiss Society of Infectious disease
the Swiss Society of Internal Medicine
the Swiss Respiratory Society
Impact factor Swiss Medical Weekly 
0 . 7 7 0
1 . 5 3 7
1 . 1 6 2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
1
9
9
5
1
9
9
6
1
9
9
7
1
9
9
8
1
9
9
9
2
0
0
0
2
0
0
2
2
0
0
3
2
0
0
4
Schweiz Med Wochenschr (1871–2000)
Swiss Med Wkly (continues Schweiz Med Wochenschr from 2001) 
Editores Medicorum Helveticorum
